Why is Olympus stock plunging today?

Olympus Corp. stock experienced an abrupt 13.6% drop to ¥1,756 on Wednesday after the U.S. Food and Drug Administration (FDA) issued a formal warning letter to the Japanese medical device maker. The warning, stemming from inspections conducted at six of the company's facilities in late 2025, relates to quality management system and process observations.

This sudden decline marks one of Olympus' sharpest single-day drops in over a year, despite the company's reassurance that the warning will not disrupt production or impact financial results.

Olympus has faced a series of FDA recalls and early alerts in the past two years, leading to revenue losses, management time, and increased restructuring costs. The company had previously outlined plans to significantly overhaul its operations to meet FDA requirements, and is currently in the process of carrying out this restructuring. However, the market's reaction to the FDA warning has been swift and severe, with Japan's Nikkei 225 adding only 0.32% and the Topix declining by 0.11% on the same day.